Home > Research projects >Projects in Clinical Studies

The Introduction of Hemay007

       Hemay007, a proprietary new chemical entity of the immunomodulatory agent, is a new treatment for Inflammatory Bowel Disease (IBD).

IBD represents a chronic intestinal inflammation usually diagnosed in one of it’s two major forms: Ulcerative Colitis (UC) and Crohn’s Disease (CD). The recorded incidences of IBD varies depending on location, from Europe, with UC incident rate of 505 per 100,000 persons; CD, 322 per 100,000 persons, to China with UC incident rate being only 11.6 per 100,000 persons; CD, 1.4 per 100,000 persons[1-2].  The etiology and pathogenesis of IBD involves a complex interaction between genetic materials, the activation of antigen stimulation and the immune system, along with external factors. Diarrhea, abdominal pain and, in some cases, Hematochezia are the most common clinical effects of IBD. IBD also has a massive impact on the patient’s education, work, social and family life. The increased rate for Colon Cancer is also a known outcome from IBD.

Current treatment options for IBD include surgical procedures, immune suppressant, Cortisoid and biological agents which all have shown limited efficiency, while demonstrating severe side effects.

Preliminary evidence indicates that Hemay007 has the potential to become a successful treatment option for patients diagnosed with IBD. Hemay007 is currently undergoing clinical trials in Australia.





1] Molodecky NA, Soon S, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 2012, 142 (1): 46-54. e42.


[2] Xue LY, Ouyang Q, Huang ZH, Zhou XG, Chen W.. Research progress of IBD in recent 20 years in China: a literature review of the past 20 years. International Journal of Gastroenterology, 2013, 33 (4): 276 - 278.





All rights reserved (2017), tianjin ICP for 05010040